ReviewCell communication and signaling : CCS2025
Immunosenescence promotes cancer development: from mechanisms to treatment strategies.
Review in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- The long-lived immune system of centenarians.Nature reviews. Immunology · 2026Review
- Review
- Age- and sex- related patterns in hematobiochemical and anthropometric parameters of Macaca monkeys.GeroScience · 2026Article
- Striking the right balance with type I interferon signalling in cancer.Nature reviews. Cancer · 2026Review
- Insights into the therapeutic strategies for aging and aging-associated diseases.Signal transduction and targeted therapy · 2026Review
- Hematopoietic Aging and Leukemia: Mechanistic and Therapeutic Insights.International journal of molecular sciences · 2026Review
- Inflammaging: Immune-Metabolic Crosstalk Between the Prostate-Testis and Musculoskeletal System.International journal of molecular sciences · 2026Review
- Second primary malignancy risk after thymic epithelial tumors: a Surveillance, Epidemiology, and End Results analysis integrating multiple primary-standardized incidence ratio and competing-risk models.Journal of thoracic disease · 2026Article
- Network Rewiring in the Aging Immune System: From Chronic Inflammation to Age-Related Pathologies.Cells · 2026Review
- Association of visceral obesity with Helicobacter pylori seropositivity and mortality in US adults.BMC infectious diseases · 2026Article
- The PARP inhibitor olaparib promotes senescence in murine macrophages.GeroScience · 2026Article
- Bridging aging and colorectal cancer: synergistic roles of inflammaging and immunosenescence.Frontiers in immunology · 2026Review
- Decoding the tumor-aging axis: from bench to clinical.Frontiers in immunology · 2026Review
- Immunosenescence in prostate cancer: from aging-related immune dysfunction to therapeutic opportunities.Frontiers in immunology · 2026Review
- Exercise interventions remodel the aging microenvironment to improve prognosis in older patients with cancer.Frontiers in immunology · 2026Review
- Neurotoxicity of immune checkpoint inhibitors: a retrospective pharmacovigilance study using FAERS database.Frontiers in immunology · 2026Article
- Molecular Mechanisms Driving Metastatic Progression Within the Aged Tumor Microenvironment.International journal of molecular sciences · 2025Review
- Immunosenescence and organoids: pathophysiology and therapeutic opportunities.Immunity & ageing : I & A · 2025Review
- Molecular Landscape of Prostate Cancer Across Age Groups: Impact on Prognosis and Treatment Outcomes.International journal of molecular sciences · 2025Review
- Senescent macrophages in tumor: phenotypes, roles, and interventions.Cell death & disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The body's innate immune system plays a pivotal role in identifying and eliminating cancer cells. However, as the immune system ages, its functionality can deteriorate, becoming dysfunctional, inefficient, or even inactive-a condition referred to as immunosenescence. This decline significantly increases the risk of malignancies. While the pro-cancer effects of T-cell aging have been widely explored, there remains a notable gap in the literature regarding the impact of aging on innate immune cells, such as macrophages and neutrophils. This review seeks to address this gap, with emphasis on these cell types. Furthermore, although certain cancer immunotherapies, including immune checkpoint inhibitors (ICIs), have demonstrated efficacy across a broad spectrum of cancers, elderly patients are less likely to derive clinical benefit from these treatments. In some cases, they may even experience immune-related adverse events (irAEs). While senolytic strategies have shown promise in exerting anti-cancer effects, their adverse reactions and potential off-target effects present significant challenges. This review aims to elucidate the pro-cancer effects of immunosenescence, its implications for the efficacy and safety of ICIs, and potential anti-aging treatment strategies. In addition, optimizing anti-aging therapies to minimize adverse reactions and enhance therapeutic outcomes remains a critical focus for future research endeavors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.